Project Farma Integrates Oracle Cloud to Streamline Pharmaceutical Facility Construction
Chicago, Thursday, 4 June 2026.
On June 3, 2026, Project Farma adopted Oracle’s cloud technology to manage complex pharmaceutical facility builds, ensuring massive $500 million capital projects remain on schedule and inspection-ready.
Addressing the Scale of Modern Pharma Manufacturing
Before this technological shift, Project Farma—a patient-focused life sciences consulting firm operating under the PerkinElmer corporate umbrella [1] [alert! ‘PerkinElmer spun off several divisions and rebranded its life sciences business as Revvity (NYSE: RVTY) in 2023, though recent corporate press materials for Project Farma continue to reference the legacy PerkinElmer name’]—had already established a massive footprint in the biotechnology sector [1]. Prior to June 1, 2026, the company had successfully managed more than 400 large-scale capital projects and executed over 100 facility builds, expansions, and retrofits [1]. Their portfolio includes the industrialization of more than 10 commercial cell, gene, and novel therapies, overseeing technical operations capital investments that exceed $6 billion [1]. The sheer scale of these operations highlights the intricate logistics required to bring modern, life-changing therapeutics from the laboratory to the commercial market [1][GPT].
The Oracle Primavera Cloud Solution
To bridge this operational gap, Project Farma announced on June 3, 2026, that it is formally expanding its Project Management Information System (PMIS) and Project Controls offerings by integrating Oracle Primavera Cloud (OPC) [1]. This managed service provides biotechnology and pharmaceutical organizations with purpose-built visibility from the very first day of a project, eliminating the need for these companies to build internal software capabilities from scratch [1]. Glen Colaco, Senior Director of Project Controls & PMIS at Project Farma, emphasized that the primary objective is to equip pharmaceutical capital programs with a fully independent and dedicated Oracle OPC environment [1]. This ensures that sensitive project data remains protected, financial controls stay clean, and manufacturing facilities are delivered on time while being fully inspection-ready [1].
Financial and Operational Implications
For biotech executives, the financial stakes of these capital projects are monumental [GPT]. Looking at Project Farma’s historical baseline of managing over $6 billion across more than 400 large-scale capital projects [1], the average capital investment per project equates to 15.000 million dollars. However, with new individual facility builds frequently exceeding the $500 million mark [1], the financial risk of delays or compliance failures has grown exponentially [GPT]. By leveraging Oracle’s advanced cloud infrastructure, Project Farma is effectively mitigating these risks, ensuring that massive capital investments translate into operational, inspection-ready manufacturing hubs capable of efficiently delivering next-generation therapies to patients [1].